BioVie (BIVI)
Develops bezisterim and continuous-infusion terlipressin therapies.
Something off on this page? Send us feedback.
Develops bezisterim for neurological conditions and BIV201, a continuous-infusion terlipressin formulation for advanced cirrhosis complications. With no approved products or sales, its research-led model relies on clinical results, regulatory clearance, financing, outside providers, and partners.
Develops investigational therapies for neurological and neurodegenerative disorders and advanced liver disease. Its oral small-molecule bezisterim is in studies for early Parkinson's disease and Long COVID; an earlier Alzheimer's study became underpowered after patient data from noncompliant sites were excluded. BIV201 is a continuous-infusion terlipressin formulation for complications of cirrhosis and ascites, designed for a portable pump and prefilled syringe.
Operates from Nevada with a clinical office in San Diego and all tangible assets in the United States. With no approved products or product revenue, its research financing supports clinical development while manufacturing and commercialization depend on contractors, consultants, regulators, capital, and potential partners. Advancing BIV201's proposed late-stage study depends on a partner, while a government grant reimburses qualifying Long COVID study costs.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.0M · Total debt $275.4K · Total assets $14.3M · Shareholders' equity $10.3M
- Revenue
- $0
- Operating income
- −$5.7M
- Net income
- −$5.6M
No dividends on record.
| Institutions32 holders · as of Mar 31, 2026 | 13.67% | 1.03M shares | |
| Insiders6 holders · as of Aug 28, 2026 | 0.58% | 44.1K shares | |
| Strategic holders1 holder · as of Aug 19, 2026 | 9.11% | 687.3K shares | |
| Otherremainder | 76.64% | 5.78M shares |
7.54M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alta Partners LLCStrategic | 9.11% | 687,321 | 13Gfiled Aug 19, 2026 ↗ |
Diametric Capital, LPInstitution | 4.91% | 370,000 | 13Fas of Mar 31, 2026 |
Prelude Capital Management, LLCInstitution | 1.22% | 92,063 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.12% | 84,203 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.11% | 84,067 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Cuong V. Do | director, officer: President & CEO | +15,210 | $2.08 |
| Aug 28, 2026 | Joanne Wendy Kim | officer: Chief Financial Officer | +2,500 | $2.18 |
| Aug 28, 2026 | Amy Suzon Chappell | director | +727 | $2.16 |
| Aug 28, 2026 | Joseph M. Palumbo | officer: Chief Medical Officer | +4,843 | $2.16 |
- AbbVie
Early-Parkinson’s oral treatment rivalry with tavapadon.
- Eli Lilly
Approved early-Alzheimer’s benchmark with Kisunla.
- Biogen
Approved early-Alzheimer’s benchmark with Leqembi.
- Amneal Pharmaceuticals
Levodopa standard-of-care rival in Parkinson’s disease.
- Supernus Pharmaceuticals
Parkinson’s infusion and symptomatic-treatment rival.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioVie | $2.03 | +0.50% | $15.3M | — | — | — | — |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Eli Lilly | $1,165.19 | +0.50% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Biogen | $224.80 | +0.94% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Amneal Pharmaceuticals | $18.20 | +0.72% | $5.77B | 37.0 | 18.1 | 1.8 | +9.9% |
| Supernus Pharmaceuticals | $43.90 | −0.30% | $2.56B | — | 15.2 | 3.1 | +32.4% |
| Median | 39.2 | 17.2 | 3.3 | +10.2% |